- Home
- FTEL vs CANF Comparison
FTEL vs CANF Comparison
Compare FTEL & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTEL
- CANF
- Stock Information
- Founded
- FTEL 2007
- CANF 1994
- Country
- FTEL Australia
- CANF Israel
- Employees
- FTEL N/A
- CANF N/A
- Industry
- FTEL
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- FTEL
- CANF Health Care
- Exchange
- FTEL Nasdaq
- CANF Nasdaq
- Market Cap
- FTEL 9.1M
- CANF 9.6M
- IPO Year
- FTEL 2023
- CANF N/A
- Fundamental
- Price
- FTEL $0.59
- CANF $0.67
- Analyst Decision
- FTEL
- CANF Strong Buy
- Analyst Count
- FTEL 0
- CANF 2
- Target Price
- FTEL N/A
- CANF $14.50
- AVG Volume (30 Days)
- FTEL 142.6K
- CANF 135.8K
- Earning Date
- FTEL 04-28-2025
- CANF 08-26-2025
- Dividend Yield
- FTEL N/A
- CANF N/A
- EPS Growth
- FTEL N/A
- CANF N/A
- EPS
- FTEL N/A
- CANF N/A
- Revenue
- FTEL $4,990,695.00
- CANF $560,000.00
- Revenue This Year
- FTEL N/A
- CANF $461.72
- Revenue Next Year
- FTEL N/A
- CANF N/A
- P/E Ratio
- FTEL N/A
- CANF N/A
- Revenue Growth
- FTEL 29.02
- CANF N/A
- 52 Week Low
- FTEL $0.36
- CANF $0.63
- 52 Week High
- FTEL $49.50
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- FTEL 61.01
- CANF 41.47
- Support Level
- FTEL $0.39
- CANF $0.64
- Resistance Level
- FTEL $0.68
- CANF $0.68
- Average True Range (ATR)
- FTEL 0.06
- CANF 0.02
- MACD
- FTEL 0.02
- CANF 0.01
- Stochastic Oscillator
- FTEL 68.51
- CANF 91.25
About FTEL Fitell Corporation
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).